Angiotensin II Receptor Blocker And Neprilysin Inhibitor Sacubitril/valsartan Attenuates Experimental Pulmonary Hypertension

被引：0
|
作者：
Clements, Richard T.
Vang, Alexander
Kue, Nouaying R.
Mancini, Thomas
Morrison, Alan R.
McCullough, Danielle J.
Mallem, Krishna
Choudhary, Gaurav
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A17134
引用
收藏
页数：2
相关论文
共 50 条
  • [11] The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
    Kario, Kazuomi
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (01)
  • [12] Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
    Ayalasomayajula, Surya
    Schuehly, Uwe
    Pal, Parasar
    Chen, Fabian
    Zhou, Wei
    Sunkara, Gangadhar
    Langenickel, Thomas H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 926 - 936
  • [13] Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor
    Ayalasomayajula, Surya P.
    Langenickel, Thomas H.
    Jordaan, Pierre
    Zhou, Wei
    Chandra, Priyamvada
    Albrecht, Diego
    Pal, Parasar
    Rajman, Iris
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (09) : 1065 - 1073
  • [14] Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
    Hui Zhang
    Gangqiong Liu
    Wenping Zhou
    Wenjing Zhang
    Kai Wang
    Jinying Zhang
    Scientific Reports, 9
  • [15] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1461 - 1478
  • [16] Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor
    Surya P. Ayalasomayajula
    Thomas H. Langenickel
    Pierre Jordaan
    Wei Zhou
    Priyamvada Chandra
    Diego Albrecht
    Parasar Pal
    Iris Rajman
    Gangadhar Sunkara
    European Journal of Clinical Pharmacology, 2016, 72 : 1065 - 1073
  • [17] Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2018, 57 : 105 - 123
  • [18] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2017, 56 : 1461 - 1478
  • [19] The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy
    Tetsufumi Yamamoto
    Masataka Sata
    Daiju Fukuda
    Shinichi Takamoto
    Basic Research in Cardiology, 2005, 100 : 84 - 91
  • [20] In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
    Jovanovic, Jelena Dorovic
    Antonijevic, Marko
    Vojinovic, Radisa
    Filipovic, Nenad D.
    Markovic, Zoran
    RSC ADVANCES, 2022, 12 (46) : 29719 - 29726
12345